Sanghnomics: The government’s move to curb 10-minute deliveries reflects a broader policy shift towards safeguarding gig ...
The New York-based AI biotech will use its AMICA-OS platform to analyze clinical immune data for BMS, aiming to inform patient stratification, biomarkers, and trial decisions.
A new consensus document developed by The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium was published in JCO ...
The Chosun Ilbo on MSN
NVIDIA, Eli Lilly launch physical AI drug development institute
On the 12th (local time), the ‘JP Morgan Healthcare Conference’ opened in San Francisco, U.S. The biggest topic at this ...
The Graft Versus Host Disease (GvHD) market across the seven major markets (7MM) is anticipated to witness substantial ...
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...
In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
The increasing complexity of embedded systems within battery management necessitates robust testing methodologies that ...
Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour BioMed for a multiyear research deal. The new pact will see the companies ...
Meta is giving Instagram users a rare glimpse into why certain posts are showing up on their Reels, the platform’s feed of algorithmically curated videos. Starting today, users will now see a list of ...
Analysts had noted “unease” from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a “significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback